Oncotarget

Research Papers:

Increased circulating CD4+FOXP3+ T cells associate with early relapse following autologous hematopoietic stem cell transplantation in multiple myeloma patients

Egor V. Batorov _, Marina A. Tikhonova, Natalia V. Pronkina, Irina V. Kryuchkova, Vera V. Sergeevicheva, Svetlana A. Sizikova, Galina Y. Ushakova, Tatiana A. Aristova, Dariya S. Batorova, Elena V. Menyaeva, Andrey V. Gilevich, Ekaterina Y. Shevela, Alexander A. Ostanin and Elena R. Chernykh

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:27305-27317. https://doi.org/10.18632/oncotarget.25553

Metrics: PDF 535 views  |   HTML 807 views  |   ?  


Abstract

Egor V. Batorov1, Marina A. Tikhonova1, Natalia V. Pronkina2, Irina V. Kryuchkova3, Vera V. Sergeevicheva3, Svetlana A. Sizikova3, Galina Y. Ushakova3, Tatiana A. Aristova3, Dariya S. Batorova3, Elena V. Menyaeva4, Andrey V. Gilevich5, Ekaterina Y. Shevela1, Alexander A. Ostanin1 and Elena R. Chernykh1

1Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

2Laboratory of Clinical Immunology, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

3Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

4Clinical Diagnostic Laboratory, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

5Intensive Care Unit, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

Correspondence to:

Egor V. Batorov, email: Ebatorov@gmail.com

Keywords: CD4+FOXP3+; autologous hematopoietic stem cell transplantation; immune recovery; multiple myeloma; relapse

Received: April 19, 2018     Accepted: May 19, 2018     Published: June 05, 2018

ABSTRACT

We investigated dynamics of CD4+FOXP3+ T cell recovery following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM) patients.

Circulating CD4+FOXP3+ T cells of 79 MM patients were evaluated using flow cytometry before HDC with auto-HSCT, at the day of engraftment, and following 6 and 12 months.

Percentage of CD4+FOXP3+ T cells restored rapidly following auto-HSCT, became higher than pre-transplant level at the day of engraftment and then subsequently decreased for a year. CD4+FOXP3+ T cells at the time of engraftment were increased in patients with the relapse or progression of MM during 12 months following auto-HSCT (n=10) compared to non-relapsed patients (n=50): 6.7% (5.3—8.9%) vs 4.9% (2.8—6.6%); PU = 0.026. Area under the curve was 0.72 (95% CI: 0.570—0.878; p=0.026). Circulating CD4+FOXP3+ T cell count was not associated with the percentage of myeloma plasma cells in a bone marrow but depended on its amount in autografts.

Conclusions: Relative count of CD4+FOXP3+ T cells restored rapidly following auto-HSCT (at the day of engraftment), became higher than pre-transplant level and then subsequently decreased for a year. Their excess at the time of engraftment is associated with early relapse.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25553